SCHEMBL133966

SCHEMBL133966

[NH]C(=O)NSc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.40
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
HPGD P15428 4/20 0.36
ALDH1A1 P00352 3/20 0.36
MTNR1A P48039 4/20 0.36
MTNR1B P49286 4/20 0.36
CYP3A4 P08684 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 5/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
MGLL Q99685 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 2/20 0.35
RECQL P46063 1/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5178134 0.81 FFAR1 (0.43) FFAR1NPC1RAB9AHPGDALDH1A1
SCHEMBL132621 0.81 SMN1; SMN2 (0.46) FFAR1NPC1RAB9AHPGDALDH1A1
SCHEMBL3070802 0.81 FFAR1 (0.43) FFAR1NPC1RAB9AHPGDALDH1A1
SCHEMBL10431593 0.77 MTNR1A (0.48) FFAR1NPC1RAB9AHPGDALDH1A1
SCHEMBL3071125 0.77 FFAR1 (0.45) FFAR1NPC1RAB9AHPGDALDH1A1
SCHEMBL158241 0.77 SIRT1 (0.42) FFAR1NPC1RAB9AHPGDALDH1A1
SCHEMBL11262828 0.76 NPC1 (0.48) NPC1RAB9AHPGDALDH1A1MAPT
SCHEMBL27502838 0.76 NPC1 (0.53) NPC1RAB9AHPGDALDH1A1CYP3A4
SCHEMBL9721632 0.76 CYP1A2 (0.47) FFAR1NPC1RAB9AHPGDALDH1A1
SCHEMBL11263588 0.75 HDAC8 (0.47) NPC1RAB9AHPGDCYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
EP-1844766-B1 Inhibitors against the production and release of inflammatory cytokines INST MED MOLECULAR DESIGN INC (JP) 2012-04-18 EP disclosed
EP-1352650-B1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES INST MED MOLECULAR DESIGN INC (JP) 2012-03-07 EP disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 US disclosed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 US disclosed
US-20080318956-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-12-25 US disclosed
US-20080249071-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-10-09 US disclosed
EP-1847263-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-24 EP disclosed
EP-1844766-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-17 EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 US disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 EP disclosed
EP-0549752-B1 PROTEIN SEQUENCING BECKMAN COULTER INC (US) 1999-03-17 EP disclosed
EP-0884324-A2 Method for generating an anilinothiozolinone by treatment of a phenylthiocarbamyl amino acid with a Lewis acid in protein sequencing Beckman Coulter, Inc. (US) 1998-12-16 EP disclosed
US-5270213-A Protein sequencing PORTON INSTRUMENTS, INC. (US) 1993-12-14 US disclosed
EP-0549752-A1 PROTEIN SEQUENCING BECKMAN INSTRUMENTS, INC. (US) 1993-07-07 EP disclosed
WO-1993000355-A1 PROTEIN SEQUENCING PORTON INSTRUMENTS, INC. (US) 1993-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A FFAR1 872/4885NPC1 896/4885RAB9A 997/4885
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A FFAR1 928/4885NPC1 978/4885RAB9A 1124/4885
US-20080249071-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A FFAR1 928/4885NPC1 978/4885RAB9A 1124/4885
US-20080318956-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A FFAR1 928/4885NPC1 978/4885RAB9A 1124/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB FFAR1 1690/4885NPC1 1519/4885RAB9A 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.